<DOC>
	<DOCNO>NCT02312544</DOCNO>
	<brief_summary>To evaluate safety IOP lower efficacy OTX-TP , sustain release travoprost drug product , place canaliculus eyelid compare Timolol Maleate Ophthalmic Solution , 0.5 % treatment subject open angle glaucoma ocular hypertension . The study design assess clinically meaningful response treatment powered measure efficacy endpoint statistical significance .</brief_summary>
	<brief_title>Phase 2b Study Evaluating Safety Efficacy OTX-TP Compared Timolol Drops Treatment Subjects With Open Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Subject must document diagnosis ocular hypertension , open angle glaucoma ( without pseudoexfoliation pigment dispersion component ) . Subject mean baseline IOP follow washout least 1 eye ( eye ) ≥ 24mmHg Hour 0 ( T0 ) Baseline Visit 1 Baseline Visit 2 ( Day 1 ) Subject mean baseline IOP follow washout least 1 eye ( eye ) : ≥ 22mmHg ( T0 + 4h ) ( T0 + 8h ) Baseline Visit 1 ( note : eye must meet IOP eligibility criterion 4 baseline assessment ) Washout IOP must ≤ 34mmHg eye time point Baseline Visit 1 Baseline Visit 2 ( Day 1 ) Subject form glaucoma open angle glaucoma ( without pigment dispersion pseudoexfoliation component ) . Subject mean baseline IOP &gt; 34 mmHg either eye time point Baseline Visits 1 2 ( Day 1 ) . Subject BCVA worse 0.6 logMAR ( 20/80 Snellen ) either eye measure use ETDRS chart . Subject know suspected allergy and/or hypersensitivity travoprost , timolol , fluorescein component study product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>